For Precision Medicine to Achieve Its Potential, Life Science Leaders Embrace New Data and AI Models
Summary
Sponsored by Medidata (NASDAQ: MDSO), Thermo Fisher Scientific, and Bristol-Myers Squibb, the survey report highlights the need for data-centric, AI tools and a connected ecosystem in the age of precision medicine. Life science executives noted in the survey that new strategies are needed to empower precision medicine initiatives: “The big opportunity to become more efficient and generate better evidence comes from using digital platforms to connect people in new ways. Powered by artificial intelligence and delivered by top-ranked industry experts, Medidata helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata and its companies, Acorn AI and SHYFT, serve 1,300 customers and partners worldwide and empower more than 150,000 certified users every day to create hope for millions of patients. Discover the future of life science: www.medidata.com Vantage is Newsweek’s thought leadership division that combines meticulous research and expert analysis to explore topics that are defining the global business environment.
Classifications
AskAI Classifications
LabelsLinked Companies
